The speed at which bioprinting can produce viable tissues for research significantly accelerates the testing and development cycles of gender-specific medications. This rapid iteration process means that new treatments can reach the market faster, addressing urgent healthcare gaps more efficiently.
- Log in or register to contribute
Contribute to three or more articles across any domain to qualify for the Contributor badge. Please check back tomorrow for updates on your progress.